戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 e and mean residence time compared to native drug formulation.
2 g, release and in vitro metabolism of a dual drug formulation.
3 rtant polymeric excipient frequently used in drug formulation.
4 irst generation NPs that largely facilitated drug formulation.
5 allenges in peptide-functionalized liposomal drug formulation.
6 al industry to store and administer antibody drug formulations.
7 y, stability, efficacy, and even toxicity of drug formulations.
8 for preserving the stability and efficacy of drug formulations.
9 rview of its application in traditional oral drug formulations.
10 her cutting agents commonly found in illicit drug formulations.
11 or neonates and infants and lack of suitable drug formulations.
12 uced toxicity as compared to the nontargeted drug formulations.
13 ly one third of that achieved for the single drug formulations.
14 a synergistic anti-inflammatory effect of PS/drug formulations.
15 oART can enhance viral clearance over native drug formulations.
16 rker of extravasation potential of liposomal drug formulations.
17 ve produced long circulating and very stable drug formulations.
18 ence issues and, availability of appropriate drug formulations.
19 stry to establish the bioequivalence between drug formulations.
20 -resistance mutations (HIVDRMs), and limited drug formulations.
21 sing cyclodextrin, an approved ingredient of drug formulations.
22 stems and drug components in multifunctional drug formulations.
23                              In a given GRIR drug formulation, accuracy, response time, and reversibi
24 rug-food interactions for specific drugs and drug formulations, additional avenues need to be explore
25                                  Amphiphilic drug formulation additives based on palmitic acid-modifi
26 ageous than a combination of targeted single drug formulations administered at the same drug ratio.
27 y virus (HIV), antiretroviral therapy (ART), drug formulation, age, and body size with their pharmaco
28                       The resulting specific drug formulation agents render insoluble drugs water-sol
29 tive, further complicates an already complex drug formulation and has the potential to slow regulator
30 rfeit, require no alteration of the existing drug formulation and minimal alteration of the manufactu
31  per gram over 24 h, and optimization of the drug formulation and quantity has led to minimized oxida
32 rthermore, combination of the hydrogel-based drug formulation and the anti-PD1 ICB therapy results in
33 singly being used to help identify effective drug formulations and derisk against undesirable crystal
34  that showed a similar efficacy to free dual drug formulations and even enhanced anti-cancer effects
35 eparin, an extensively used anticoagulant in drug formulations and medical devices, is critical to en
36  should help advance the development of oral drug formulations and might also be useful for drug scre
37 n the typically non-physiological aspects of drug formulations and the homeostatic IM environment may
38 re the suprachoroidal injection of different drug formulations and to characterize the safety and pha
39 nted lobes, 14 pertain to the device and the drug formulation, and 13 the inhalation profile of the s
40 aqueous solubility, which in turn influences drug formulation approaches.
41  pharmacoeconomic principles that drive oral drug formulation are discussed.
42 is translates to the clinic, where liposomal drug formulations are reported to exhibit higher efficac
43 ugs which are crucial for creating effective drugs formulations as well as improving surfactant and d
44 sed to unambiguously chemically characterize drug formulations at these length scales.
45 ortunities for the development of innovative drug formulations, biomolecule delivery, and diagnostic
46 l anatomy, challenges to nasal delivery, and drug/formulation considerations for nose to brain delive
47                         Although these novel drug formulations could contribute greatly to HIV treatm
48 ereas animals treated with the rapid-release drug formulation Cremophor EL (PTX-CrEL) or saline (cont
49  Additional factors, such as drug chemistry, drug formulations, different routes of administration, a
50 in in primary prevention include the optimal drug formulation, dosing schedule, weight-based dose sel
51 es in various applications (crystallography, drug formulation, etc.).
52  platforms, three laboratories, and multiple drug formulations following a comprehensive analysis of
53 en employed as a component of organometallic drug formulations for chemotherapy.
54 s rapid quantification of trace chemicals in drug formulations for forensic analysis or identificatio
55 r drug exposures afforded by a new amorphous drug formulation, greater than 80% inhibition of ERK pho
56 d ENG (12 months) with high stability of the drug formulation (>95%).
57                               Refinements in drug formulation have provided the ability to target dis
58 n and the development of microparticle-based drug formulations have gained increased pharmaceutical i
59 ly solution employing oils typically used in drug formulations, i.e., middle-chain triglycerides and
60 unts of active ingredients in pharmaceutical drug formulations, illicit drugs (methamphetamine, cocai
61 es are unique in their ability to load solid drug formulation in concentrated form.
62 t forms from the solubilized peptoid-peptide-drug formulation in response to phosphatase enzymes pres
63                            Here we develop a drug formulation in which a lipid-based nanoparticle (LB
64  role of novel antithrombotic strategies and drug formulations in maximizing the net benefit of antit
65 ential idea is to encapsulate the ophthalmic drug formulations in nanoparticles and to disperse these
66 curately and reproducibly separate liposomal drug formulations into their component populations and t
67              In addition, it is not clear if drug formulation is a major factor in optimizing pharmac
68  In this study, an injectable hydrogel-based drug formulation is developed to stimulate TLSs formatio
69   Application of lipid-based nanocarriers in drug formulation is one approach to improve drug safety.
70 ration, and administration of alginate-based drug formulations is a distinctive advantage.
71 the release performance of subcutaneous (SC) drug formulations is challenging due to the complex inte
72  requiring no additional measurements or new drug formulations, is one approach to improve tuberculos
73     Due to the heterogeneous nature of solid drug formulations, it is essential to characterize the d
74 the availability of pediatric antiretroviral drug formulations, it proved feasible to deliver pediatr
75 ng due to the complexity of the nanoparticle drug formulation itself and the number of pharmacokineti
76  intratumoral injections are that the liquid drug formulation may not remain localized and have unpre
77                                Exosome-based drug formulations may be applied to a wide variety of di
78 s a result, potential sites in which topical drug formulations might be sequestered post-poration and
79                                    The novel drug formulations of DSF will also serve as a good strat
80 re, we show the development of LA injectable drug formulations of the anti-TB drug rifabutin made of
81             Following this, we evaluated two drug formulations of TRAIL (TNF-related apoptosis induci
82  ongoing innovation in device technology and drug formulations on devices.
83  resistance, battery voltage, and glycol and drug formulation, on the aerosol particle size.
84 prove useful for rapid analysis of liposomal drug formulations or rapid, robust, direct measurement o
85 c decision making, the issues of infant CML, drug formulation, pharmacokinetics, and adolescent compl
86 ost observed toxicities were attributable to drug formulation (polyoxyl 35 castor oil or hyperosmolar
87          In vivo we demonstrate that the pro-drug formulation reduces application site inflammation c
88 e range of contraceptive options, varying in drug formulation, route of delivery, and discrepancy bet
89 serves to support the mechanistic design for drug formulation safety, rigor and reproducibility.
90 g adenosine concentration in blood serum and drug formulation samples.The herein described methodolog
91 LGA) nanoparticles contained in slow-release drug formulations, scaffolds and implants, are ubiquitou
92                     The model was tested for drug formulations spanning a large range of solubility a
93  achieved through topical application of the drug formulation START (0.9% sodium chloride, 1% Tween 8
94 in the antitumor field; however, appropriate drug formulations still need to be explored for specific
95 for allowance or avoidance of antiarrhythmic drug formulation substitution are suggested.
96              The application of nanoparticle drug formulations, such as nanoliposomal doxorubicin (Do
97                               Many inhalable drug formulations suffer from low respirable fractions,
98 d at different temperatures is essential for drug formulation, synthesis, purification, and crystalli
99        Polymeric nanoparticles are a type of drug formulation that enables the sustained release of a
100 ntages and limitations of recent advances in drug formulation that improve protein stability and phar
101 ell as rigorous determination of the optimal drug formulation to achieve maximum potency with minimum
102 cancer properties and DW-F5 as a forthcoming drug formulation to be evaluated as a chemotherapeutic a
103 wall include finding suitable excipients for drug formulation to enable drug release to a targeted le
104 s study describes a prototype of a universal drug formulation to vaccinate against tumors and pathoge
105 beneficial in the design and optimization of drug formulations to treat recalcitrant nail disease.
106 oach to the rapid analysis of pharmaceutical drug formulations using hyphenated ion mobility spectrom
107 for large area transdermal delivery of solid drug formulations using these porous microneedles.
108                                         This drug formulation was effective within hours by first blo
109 f individual drugs between 3-in-1 and single drug formulations were eliminated.
110                    Access to long-acting HIV drug formulations with dual activity against HBV would b
111 maceutical screening of low-molecular-weight drug formulations with high selectivity over the formula
112 elease rate compared with the large-particle drug formulation, with area under concentration-time cur
113 s in the application of cyclodextrins to new drug formulations, with emphasis on the field of anesthe
114            The development of child-friendly drug formulations would need to be carried out in parall
115                       Long-acting injectable drug formulations would shorten therapy administration a

 
Page Top